Učitavanje...
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BACKGROUND: 5-Azacitidine administered as a 7-day dosing regimen (7–0-0) is approved in high risk IPSS myelodysplastic syndrome (MDS) patients. Alternative regimens such as a 5-day (5–0-0) or 7-day with a weekend break (5–2-2) are commonly used. No randomized controlled trial has been done directly...
Spremljeno u:
| Izdano u: | BMC Hematol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5793426/ https://ncbi.nlm.nih.gov/pubmed/29435331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-017-0094-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|